查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594892

光學臨床前成像的全球市場

Optical Preclinical Imaging
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 93 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2030年，全球光學臨床前影像市場預計將達到9.369億美元

2023年全球光學臨床前影像市場估計為6.274億美元，預計2030年將達到9.369億美元，在2023-2030年分析期間複合年成長率為5.9%。生物發光/螢光成像系統是本報告分析的細分市場之一，預計複合年成長率為 7.0%，到分析期結束時將達到 5.369 億美元。在分析期間，獨立螢光成像系統領域的複合年成長率預計為 5.0%。

美國市場預計1.64億美元，中國預期複合年成長率9.2%

預計 2023 年美國光學臨床前影像市場規模將達到 1.64 億美元。中國作為世界第二大經濟體，預計到 2030 年市場規模將達到 2.207 億美元，2023-2030 年分析期間複合年成長率為 9.2%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 3.5% 和 4.7%。在歐洲，德國的複合年成長率預計為 4.3%。

全球光學臨床前影像市場—主要趨勢與促進因素總結

光學臨床前影像如何改變生物醫學研究？

光學臨床前成像已成為生物醫學研究中的革命性工具，使科學家能夠以前所未有的細節可視化活體動物模型中的細胞和分子過程。傳統上，研究人員依靠侵入性方法來監測疾病進展和治療效果，但光學成像技術的進步正在提供非侵入性的即時見解，可以幫助臨床前研究帶來一場革命。螢光和生物發光成像等技術使研究人員能夠監測細胞和亞細胞層面的生物變化，有助於更深入地了解複雜的生物機制。這種能力在癌症研究中特別有價值，光學成像使研究人員能夠追蹤腫瘤的生長、轉移和治療反應，而無需多次侵入性操作。透過允許研究人員對同一主題進行長期研究，光學成像最大限度地減少了實驗所需的動物數量，並符合生物醫學研究中的倫理考量。

除了加強癌症研究之外，光學臨床前影像還具有先進的免疫學、神經科學和感染疾病研究。即時可視化免疫細胞行為和病原體-宿主相互作用的能力提供了可以導致新治療方法發現的重要資料。例如，螢光成像可以追蹤免疫細胞對感染疾病和腫瘤的反應，從而深入了解如何調節免疫反應以改善治療結果。同樣，光學成像技術可用於神經科學研究，以監測神經活動和大腦功能。透過可視化疾病模型中的神經元通訊和退化，研究人員可以更好地了解阿茲海默症和帕金森氏症等神經退化性疾病，並為標靶治療鋪平道路。因此，光學臨床前影像處於現代生物醫學研究的前沿，並已成為增進我們對各種病理狀況理解的重要工具。

此外，將光學成像與 MRI 和 CT 等其他成像技術相結合的多模態成像系統的發展進一步提高了臨床前研究的能力。這些系統提供補充資料，提高生物學見解的精確度和深度。例如，光學成像提供了更高的靈敏度來檢測特定的生物標記物，而 CT 和 MRI 添加了結構訊息，將這些觀察置於受試者的解剖框架內。透過以這種方式整合功能和解剖資料，研究人員可以更全面地資料疾病進展和治療意義。多模態成像將光學臨床前成像帶入了新領域，鞏固了其作為轉化研究中重要技術的作用，旨在彌合臨床前知識和臨床應用之間的差距。

為什麼光學成像在藥物開發上受到青睞？

光學臨床前成像使製藥公司能夠敏感地評估候選藥物在體內的功效、分佈和安全性，並已成為藥物開發的首選技術。這種非侵入性技術為藥物發現和臨床前測試提供了一種更快、更具成本效益的方法，顯著縮短了新治療方法從實驗室到臨床試驗所需的時間。在螢光/生物發光成像中，藥物和生物標記物被標記有特定的螢光或發光探針，當它們與目標細胞或蛋白質相互作用時會發光。這些訊號提供有關藥物如何與特定生物標的相互作用的即時資訊，從而更容易評估治療效果並識別潛在的副作用。光學成像使研究人員能夠快速篩檢多種候選藥物，簡化有前途的化合物的選擇，並在進入昂貴的臨床階段之前完善劑量和給藥方法。

光學成像在藥物動力學和動態研究中也很有用，可以追蹤藥物如何在體內移動以及它們產生什麼作用。利用螢光標記，科學家可以可視化藥物在體內的吸收、分佈、代謝和排泄（ADME）過程。這些資料對於確定最佳給藥方案和了解藥物化學性質如何影響生物有效性和功效至關重要。光學成像的即時回饋對於理解抗體和基因療法等生技藥品的行為特別有價值，這些生物製劑通常需要精確的標靶和監測。此外，光學成像使研究人員能夠測量藥物在體內特定部位的生物分佈，從而使研究人員能夠確定藥物是否對其預期目標產生影響，而不會在非目標器官中積累，從而導致毒性。能達到目標。這種細節程度是其他成像技術難以達到的，凸顯了光學成像在藥物開發中的獨特優勢。

光學臨床前成像由於其在癌症、感染疾病和代謝性疾病等多種疾病模型中的靈活性，已成為轉化研究的重要工具。光學成像使製藥公司能夠使用基因工程生物體在各種疾病模型中對候選藥物進行嚴格的測試，這些生物體表達與所研究的疾病相關的特定標記。例如，研究代謝紊亂的研究人員可以利用光學成像即時觀察葡萄糖攝取和脂質代謝的變化，為新藥的治療效果提供有價值的見解。光學成像對這些疾病模型和研究目標的適應性使研究人員能夠做出資料主導的決策，從而加速發現有效和安全的治療方法，這使得光學成像在開發平臺中發揮重要作用。

光學臨床前影像如何推進精準醫學？

精準醫學領域旨在根據個別患者特徵量身定做治療，極大地受益於光學臨床前影像的進步。透過提供高度詳細的分子和細胞見解，光學成像使研究人員能夠在個人化層面上了解疾病的潛在機制，這對於開發標靶治療至關重要。這種能力在腫瘤學中特別有價值，腫瘤異質性意味著不同的患者對治療的反應不同。光學成像使研究人員能夠分析活體模型中腫瘤的分子特徵，並識別出顯示哪些患者會對特定治療產生反應的生物標記。這種精準主導的方法可以客製化治療計劃，最大限度地提高治療效果，同時最大限度地減少不必要的副作用，這是精準醫學的核心目標。

光學成像在了解影響疾病感受性和治療效果的遺傳因素方面也發揮著重要作用。例如，在基因編輯研究中，螢光標記可用於即時追蹤基因修飾的效果，顯示特定的基因修飾如何影響疾病進展或藥物療效。這將使研究人員能夠探索基因治療的潛力並評估基於 CRISPR 的治療的安全性和有效性。此外，光學成像可以可視化特定基因突變如何影響細胞路徑，使科學家能夠確定罕見和複雜疾病的潛在治療標靶。這種洞察力對於推進精準醫學至關重要，精準醫學旨在根據患者獨特的遺傳特徵和疾病特徵量身定做治療方案。

在免疫治療領域，光學臨床前影像為開發利用人體免疫系統對抗腫瘤的個人化癌症治療開闢了新的可能性。生物發光成像等光學成像技術使研究人員能夠觀察免疫細胞和腫瘤之間的相互作用，從而提供有關免疫療法在體內如何發揮作用的寶貴資料。透過追蹤免疫細胞的運動和活動，研究人員可以確定哪些類型的免疫細胞最有效地針對特定的腫瘤類型，以及腫瘤如何逃避免疫反應。這些資訊對於設計更有效的免疫療法至關重要，這些療法適合每位患者的免疫特徵並符合精準醫療的目標。透過其揭示複雜生物機制的能力，光學臨床前成像不僅促進了個性化治療的發展，而且有助於理解遺傳學、免疫和疾病之間複雜的相互作用。

是什麼推動了光學臨床前影像市場的成長？

光學臨床前成像市場的成長受到多種因素的推動，包括成像技術的進步、藥物發現投資的增加以及精準醫療的興起。臨床前研究對更準確、非侵入性和經濟高效的成像技術的需求正在刺雷射學成像系統的創新，特別是在螢光、生物發光和多模態成像方面。這些技術使研究人員能夠對疾病機制、藥物療效和生物標記表達進行高度詳細的研究，提供推動學術研究和藥物開發的關鍵資料。光學成像的可及性和靈敏度以及提供即時回饋的能力使其成為臨床前研究的寶貴工具，隨著藥物開發變得更加複雜和資料驅動，臨床前研究不斷擴大。藥物發現和疾病研究對先進成像解決方案的需求是推動光學臨床前成像市場向前發展的關鍵因素。

另一個重要的促進因素是對精準醫學的日益重視，光學臨床前影像對於根據患者個體情況開發標靶治療至關重要。由於精準醫學尋求在分子層面上了解疾病，因此光學成像提供了詢問疾病模型中的細胞和遺傳過程所需的工具，使研究人員能夠識別生物標記物，並允許您相應地調整治療方法。可視化和量化活體模型中生物標記活動的能力與精準醫學的目標一致，使得光學成像對於將臨床前見解與個人化治療聯繫起來至關重要。研究和臨床實踐中向精準醫學的持續轉變正在刺雷射學成像技術的發展。研究人員需要能夠促進個人層面資料收集和分析的工具，最終幫助創建更有效和個人化的治療方案。

此外，臨床前研究中對微創技術的日益關注正在推動光學成像的採用，以實現縱向研究，減少動物使用並提高資料一致性。光學成像的非侵入性對於對同一物件進行重複測量特別有價值，可以減少對大樣本大小的需求並滿足動物研究的道德標準。製藥公司和學術機構擴大轉向光學成像來最佳化臨床前測試。隨著對倫理研究實踐的持續支持以及對高效藥物開發平臺的需求，對光學臨床前成像解決方案的需求將穩步成長，支持生物醫學研究的進步並推動光學成像市場的成長。

部分

模式（生物發光/螢光成像系統、獨立螢光成像系統、光學+X光/光學+CT）、最終用戶（製藥/生物技術公司、研究機構、其他最終用戶）

受訪企業範例（共42例）

  • BioTek Instruments, Inc.
  • Bruker Corporation
  • Fujifilm Holdings America Corporation
  • Fujifilm Holdings Corporation
  • Magnetic Insight, Inc.
  • MBF Bioscience
  • Mediso Ltd.
  • MILabs BV
  • Miltenyi Biotec
  • MR Solutions
  • PerkinElmer, Inc.
  • TriFoil Imaging
  • UVP
  • Vieworks Co., Ltd.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP22427

Global Optical Preclinical Imaging Market to Reach US$936.9 Million by 2030

The global market for Optical Preclinical Imaging estimated at US$627.4 Million in the year 2023, is expected to reach US$936.9 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Bioluminescence / Fluorescence Imaging Systems, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$536.9 Million by the end of the analysis period. Growth in the Standalone Fluorescence Imaging Systems segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$164.0 Million While China is Forecast to Grow at 9.2% CAGR

The Optical Preclinical Imaging market in the U.S. is estimated at US$164.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$220.7 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Optical Preclinical Imaging Market - Key Trends & Drivers Summarized

How Has Optical Preclinical Imaging Transformed Biomedical Research?

Optical preclinical imaging has emerged as a transformative tool in biomedical research, enabling scientists to visualize cellular and molecular processes in live animal models with unprecedented detail. Traditionally, researchers relied on invasive methods to observe disease progression and treatment efficacy, but advancements in optical imaging technology have revolutionized preclinical studies by offering non-invasive, real-time insights. Techniques such as fluorescence and bioluminescence imaging allow researchers to monitor biological changes at cellular and subcellular levels, facilitating a deeper understanding of complex biological mechanisms. This capability is especially valuable in cancer research, where optical imaging can track tumor growth, metastasis, and responses to therapies without the need for multiple invasive procedures. By allowing researchers to conduct longitudinal studies on the same subject, optical imaging minimizes the number of animals required for experiments, which aligns with ethical considerations in biomedical research.

In addition to enhancing cancer research, optical preclinical imaging has advanced studies in immunology, neuroscience, and infectious diseases. The ability to visualize immune cell behavior and pathogen-host interactions in real-time provides critical data that can drive new therapeutic discoveries. For example, fluorescence imaging can track immune cells as they respond to infections or tumors, providing insights into how immune responses could be modulated to improve treatment outcomes. Similarly, optical imaging techniques are instrumental in neuroscience research, where they are used to monitor neural activity and brain function. By visualizing how neurons communicate or degenerate in disease models, researchers can better understand neurodegenerative diseases like Alzheimer’s and Parkinson’s, paving the way for targeted therapies. Thus, optical preclinical imaging has established itself as an indispensable tool for advancing our understanding of a wide array of medical conditions, positioning it at the forefront of modern biomedical research.

Moreover, the development of multimodal imaging systems, which combine optical imaging with other imaging techniques such as MRI or CT, has further extended the capabilities of preclinical studies. These systems provide complementary data that enhance the accuracy and depth of biological insights. For instance, while optical imaging offers high sensitivity for detecting specific biomarkers, CT and MRI add structural information that contextualizes those findings within the anatomical framework of the subject. This integration of functional and anatomical data enables researchers to build a more comprehensive picture of disease progression and therapeutic impact. With multimodal imaging, optical preclinical imaging is entering new realms of sophistication, solidifying its role as a pivotal technology for translational research aimed at bridging the gap between preclinical findings and clinical applications.

What Makes Optical Imaging a Preferred Technique in Drug Development?

Optical preclinical imaging has become a preferred technique in drug development, allowing pharmaceutical companies to evaluate the efficacy, distribution, and safety of drug candidates in vivo with high sensitivity. This non-invasive technique offers a faster and more cost-effective method for drug discovery and preclinical testing, significantly reducing the time it takes to bring new treatments from the laboratory to clinical trials. In fluorescence and bioluminescence imaging, drugs or biological markers are tagged with specific fluorescent or luminescent probes that emit light when interacting with target cells or proteins. These signals provide real-time information on how drugs interact with specific biological targets, making it easier to assess therapeutic effectiveness and identify potential side effects. With optical imaging, researchers can quickly screen multiple drug candidates, streamline the selection of promising compounds, and refine dosage and delivery methods before moving into costly clinical stages.

Furthermore, optical imaging is instrumental in pharmacokinetics and pharmacodynamics studies, which track how drugs move through and affect the body. By using fluorescent markers, scientists can visualize drug absorption, distribution, metabolism, and excretion (ADME) processes within living organisms. This data is essential for determining optimal dosing regimens and understanding how a drug's chemical properties impact its bioavailability and efficacy. Optical imaging's real-time feedback is especially valuable in understanding the behavior of biologics, such as antibodies and gene therapies, which often require precise targeting and monitoring. In addition, optical imaging can measure drug biodistribution at specific sites within the body, helping researchers determine if a drug effectively reaches its intended target without accumulating in non-targeted organs, which could lead to toxicity. This level of detail is difficult to achieve with other imaging techniques, highlighting the unique advantages of optical imaging in drug development.

The flexibility of optical preclinical imaging to work across various disease models, including cancer, infectious diseases, and metabolic disorders, has made it an essential tool in translational research. Optical imaging enables pharmaceutical companies to conduct rigorous testing of drug candidates in a wide range of pathological models, often using genetically modified organisms that express specific markers relevant to the disease being studied. For instance, researchers studying metabolic disorders can use optical imaging to observe changes in glucose uptake or lipid metabolism in real-time, providing valuable insights into the therapeutic effects of new drugs. This adaptability of optical imaging across disease models and research goals underscores its vital role in the drug development pipeline, empowering researchers to make data-driven decisions that accelerate the discovery of effective and safe treatments.

How Is Optical Preclinical Imaging Advancing Precision Medicine?

The field of precision medicine, which aims to customize treatments based on individual patient characteristics, has greatly benefited from advancements in optical preclinical imaging. By providing highly detailed molecular and cellular insights, optical imaging enables researchers to understand the underlying mechanisms of diseases at a personalized level, which is essential for developing targeted therapies. This capability is particularly valuable in oncology, where the heterogeneity of tumors means that different patients respond to treatments differently. With optical imaging, researchers can analyze the molecular profile of tumors in live models, identifying biomarkers that indicate which patients may respond to specific therapies. This precision-driven approach allows for the customization of treatment plans, maximizing therapeutic outcomes while minimizing unnecessary side effects, which is the core objective of precision medicine.

Optical imaging also plays a critical role in understanding genetic factors that influence disease susceptibility and treatment responses. In gene-editing studies, for example, fluorescent markers can be used to track the effects of gene modifications in real-time, showing how certain genetic alterations impact disease progression or drug efficacy. This allows researchers to explore potential gene therapies and assess the safety and effectiveness of CRISPR-based treatments. Additionally, optical imaging can visualize how specific genetic mutations affect cellular pathways, enabling scientists to identify potential therapeutic targets for rare and complex diseases. This level of insight is essential for advancing precision medicine, where the goal is to tailor treatments based on a patient’s unique genetic profile and disease characteristics.

In the realm of immunotherapy, optical preclinical imaging has opened up new possibilities for developing personalized cancer treatments that harness the body’s immune system to fight tumors. Optical imaging techniques, such as bioluminescence imaging, allow researchers to observe immune cell interactions with tumors, providing valuable data on how immunotherapies perform within a living organism. By tracking the movement and activity of immune cells, researchers can identify which types of immune cells are most effective in targeting specific tumor types and monitor how tumors evade immune responses. This information is crucial for designing more effective immunotherapies tailored to individual patients' immune profiles, aligning with the goals of precision medicine. Through its ability to reveal intricate biological mechanisms, optical preclinical imaging is not only advancing the development of personalized treatments but also helping to unravel the complex interactions between genetics, immunity, and disease.

What Is Fueling the Growth in the Optical Preclinical Imaging Market?

The growth in the optical preclinical imaging market is driven by several factors, including advancements in imaging technology, increased investment in drug discovery, and the rise of precision medicine. The demand for more accurate, non-invasive, and cost-effective imaging techniques in preclinical studies has fueled innovation in optical imaging systems, particularly in fluorescence, bioluminescence, and multimodal imaging. These technologies allow researchers to conduct highly detailed studies on disease mechanisms, drug efficacy, and biomarker expression, providing critical data that drive both academic research and pharmaceutical development. The accessibility and sensitivity of optical imaging, combined with its ability to deliver real-time feedback, make it a valuable tool for preclinical studies, which continue to expand as drug development becomes more complex and data-driven. This need for sophisticated imaging solutions in drug discovery and disease research is a key factor propelling the optical preclinical imaging market forward.

Another significant driver is the increasing emphasis on precision medicine, where optical preclinical imaging is essential for developing targeted therapies based on individual patient profiles. As precision medicine seeks to understand diseases at a molecular level, optical imaging provides the tools necessary to study cellular and genetic processes within disease models, enabling researchers to identify biomarkers and tailor therapies accordingly. The ability to visualize and quantify biomarker activity in live models aligns with the goals of precision medicine, making optical imaging indispensable for translating preclinical findings into personalized treatments. The ongoing shift toward precision medicine in both research and clinical practice has spurred growth in optical imaging technologies, as researchers require tools that can facilitate data collection and analysis on an individual level, ultimately helping to create more effective and personalized treatment options.

Furthermore, the growing focus on minimally invasive techniques in preclinical research is driving the adoption of optical imaging, as it allows for longitudinal studies with reduced animal usage and improved data consistency. Optical imaging’s non-invasive nature is particularly valuable for conducting repeated measures on the same subject, reducing the need for large sample sizes and aligning with ethical standards in animal research. Pharmaceutical companies and academic institutions are increasingly adopting these methods to optimize their preclinical studies, as optical imaging reduces costs and enhances experimental efficiency. With continued support for ethical research practices and the need for efficient drug development pipelines, the demand for optical preclinical imaging solutions is expected to rise steadily, supporting advancements in biomedical research and driving the growth of the optical imaging market.

SCOPE OF STUDY:

The report analyzes the Optical Preclinical Imaging market in terms of US$ Thousand by the following End-Use; Modality, and Geographic Regions/Countries:

Segments:

Modality (Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems, Optical + X-Ray / Optical + CT); End-Use (Pharma & Biotech Companies, Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • BioTek Instruments, Inc.
  • Bruker Corporation
  • Fujifilm Holdings America Corporation
  • Fujifilm Holdings Corporation
  • Magnetic Insight, Inc.
  • MBF Bioscience
  • Mediso Ltd.
  • MILabs B.V.
  • Miltenyi Biotec
  • MR Solutions
  • PerkinElmer, Inc.
  • TriFoil Imaging
  • UVP
  • Vieworks Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Economic Update
    • Optical Preclinical Imaging - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Molecular Imaging Techniques Drive Adoption of Optical Preclinical Imaging
    • Increased R&D Expenditure in Biotechnology Propels Demand for Preclinical Imaging
    • Rising Demand for Cancer Research Boosts the Need for Optical Imaging
    • Technological Advancements in Fluorescence Imaging Sets the Stage for Market Growth
    • Government Funding for Biomedical Research Strengthens the Optical Imaging Market
    • Expanding Drug Discovery Programs Drive Growth in Optical Preclinical Imaging
    • Innovations in Imaging Agents Propel Demand for Optical Imaging
    • Advancements in 3D Imaging Drive Demand for Optical Preclinical Solutions
    • Increasing Use of Imaging in Stem Cell Research Strengthens Market Growth
    • Use of Optical Imaging for Neurodegenerative Disease Research Expands Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Optical Preclinical Imaging Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Optical Preclinical Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Standalone Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Standalone Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Standalone Fluorescence Imaging Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Optical + X-Ray / Optical + CT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Optical + X-Ray / Optical + CT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Optical + X-Ray / Optical + CT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • JAPAN
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • CHINA
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • EUROPE
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Optical Preclinical Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • FRANCE
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • GERMANY
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Optical Preclinical Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • INDIA
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Optical Preclinical Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Optical Preclinical Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
  • AFRICA
    • Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030

IV. COMPETITION